HypertensionNCT06762834
Investigating the Role of Ginger Tea ORAC Value in Hypertension Management
A study testing Ginger tea and self administred Ginger tea in people with Hypertension, run by Superior University at 2 sites in Pakistan.
Trial summary
The purpose of this study is to evaluate the antihypertensive effects of ginger tea. By examining its impact on blood pressure levels, this research aims to determine whether ginger tea can be an effective, natural adjunct to conventional hypertension treatments. Read more about this study
- Who is it for?
- Ages 30 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Hypertension
- What is being tested?
- Ginger tea and self administred Ginger tea
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 2 sitesPakistan
- Study dates
- 1 Mar 2024to 1 Mar 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults aged 30-65 years
- Diagnosed with stage 1 or stage 2 hypertension
- Not currently taking antihypertensive medication
- Willing to provide informed consent and adhere to study protocols.
Who cannot join
- Pregnant or breastfeeding women
- Participants on antioxidant supplements or other herbal teas.
Trial locations and contacts
2 sites in 1 country.
Pakistan2 sites
Azra Naheed Medical College, Superior University
Lahore, Punjab Province
Chaudary Muhammad Akram Teaching Hospital, Azra Naheed Medical College, Superior University
Lahore, Punjab Province
About this study
The purpose of this study is to evaluate the antihypertensive effects of ginger tea. By examining its impact on blood pressure levels, this research aims to determine whether ginger tea can be an effective, natural adjunct to conventional hypertension treatments.
Read the detailed description
This investigation will provide insights into its potential role in reducing the burden of hypertension and improving cardiovascular health
- Conditions
- Hypertension
- Being tested
- Ginger tea, self administred Ginger tea
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ginger teaCombination product
determine the optimal dosage of ginger tea that produces significant blood pressure reduction without adverse effects.
self administred Ginger teaCombination product
To identify consumption and its correlation with blood pressure outcomes using a self- reported diary and periodic clinical assessments.
| Study group | Role | What they receive |
|---|---|---|
| Ginger Tea | Experimental | Not described Receives: Combination Product: Ginger tea |
| Self Administered Tea | Active comparator | Not described Receives: Combination Product: self administred Ginger tea |
What is being measured
The primary outcome is the main question the study is designed to answer.
Systolic Blood Pressure (SBP)
Measure changes in SBP before and after the intervention with ginger tea over a defined period.
Measured: 12 Months
Total ORAC Value
Measure the total Oxygen Radical Absorbance Capacity (ORAC) value of ginger tea consumed by participants to evaluate its antioxidant capacity and potential correlation with blood pressure changes.
Measured: 12 Months
Diastolic Blood Pressure (DBP)
Measure changes in DBP before and after the intervention with ginger tea over a defined period.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jan 2025
- Study start1 Mar 2024
- Primary completion1 Oct 2024
- Study completion1 Mar 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypertensionStudies of the same condition, open and under way.
- More trials run by Superior UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- Superior University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Muhammad Naveed Babur, Superior University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06762834
- Sponsor's protocol ID
- MSAHS/Batch-Spring23/023
- Status last verified
- Jan 2025
- First submitted
- 17 Dec 2024
- Last updated
- 8 Jan 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigating the Role of Ginger Tea ORAC Value in Hypertension Management
- ClinicalTrials.gov ID
- NCT06762834
- Acronym / sponsor ID
- MSAHS/Batch-Spring23/023
- Conditions
- Hypertension
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 50 participants (actual)
- Lead sponsor
- Superior UniversityUniversity, hospital or other
- Study start
- 1 Mar 2024 (actual)
- Primary completion
- 1 Oct 2024 (actual)
- Study completion
- 1 Mar 2025 (estimated)
- First posted
- 8 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the antihypertensive effects of ginger tea. By examining its impact on blood pressure levels, this research aims to determine whether ginger tea can be an effective, natural adjunct to conventional hypertension treatments.
Detailed description
This investigation will provide insights into its potential role in reducing the burden of hypertension and improving cardiovascular health
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Ginger Tea | Experimental | Combination Product: Ginger tea |
| Self Administered Tea | Active comparator | Combination Product: self administred Ginger tea |
Who may qualify
- Ages
- 30 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adults aged 30-65 years
- Diagnosed with stage 1 or stage 2 hypertension
- Not currently taking antihypertensive medication
- Willing to provide informed consent and adhere to study protocols.
Key exclusion criteria (2 listed)
- Pregnant or breastfeeding women
- Participants on antioxidant supplements or other herbal teas.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ginger teadetermine the optimal dosage of ginger tea that produces significant blood pressure reduction without adverse effects. | Combination product | Ginger Tea |
| self administred Ginger teaTo identify consumption and its correlation with blood pressure outcomes using a self- reported diary and periodic clinical assessments. | Combination product | Self Administered Tea |
Primary outcome
Systolic Blood Pressure (SBP)
Time frame: 12 Months
Measure changes in SBP before and after the intervention with ginger tea over a defined period.
Total ORAC Value
Time frame: 12 Months
Measure the total Oxygen Radical Absorbance Capacity (ORAC) value of ginger tea consumed by participants to evaluate its antioxidant capacity and potential correlation with blood pressure changes.
Diastolic Blood Pressure (DBP)
Time frame: 12 months
Measure changes in DBP before and after the intervention with ginger tea over a defined period.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jan 2025.
- Individual participant dataSharing planned: No
Related trials for Hypertension
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ginger tea and self administred Ginger tea in people with Hypertension, run by Superior University at 2 sites in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 8 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Systolic Blood Pressure (SBP) (time frame: 12 Months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jan 2025.